Macugen pegaptanib: Phase III data

In the double-blind, international Phase III Study A5751013 trial in 260 patients, 0.3 mg intravitreal Macugen every 6 weeks met the primary endpoint of a significantly greater

Read the full 278 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE